A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.

@article{Gidwani2016ANI,
  title={A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.},
  author={Kamlesh Gidwani and Kaisa Huhtinen and Henna Kekki and Sandra J van Vliet and Johanna Hynninen and Niina Koivuviita and Antti Perheentupa and Matti Poutanen and Annika Auranen and Seija Elisa Gr{\'e}nman and Urpo J Lamminm{\"a}ki and Olli Carp{\'e}n and Yvette van Kooyk and Kim S I Pettersson},
  journal={Clinical chemistry},
  year={2016},
  volume={62 10},
  pages={1390-400}
}
BACKGROUND Measurement of serum cancer antigen 125 (CA125) is the standard approach for epithelial ovarian cancer (EOC) diagnostics and follow-up. However, the clinical specificity is not optimal because increased values are also detected in healthy controls and in benign diseases. CA125 is known to be differentially glycosylated in EOC, potentially offering a way to construct CA125 assays with improved cancer specificity. Our goal was to identify carbohydrate-reactive lectins for… CONTINUE READING